Sonoma Pharmaceuticals (SNOA) Non-Current Debt (2011 - 2022)

Sonoma Pharmaceuticals' Non-Current Debt history runs 11 years deep, the most recent figure standing at $15000.0 for Q4 2022.

• On a quarterly basis, Non-Current Debt changed N/A year-over-year to $15000.0 in Q4 2022; TTM through Dec 2022 was $15000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $1.3 million, changed N/A from the prior year.
• Non-Current Debt steadied at $15000.0 in Q4 2022 per SNOA's latest filing, from $15000.0 in the prior quarter.
• Across five years, Non-Current Debt topped out at $1.3 million in Q2 2020 and bottomed at $12000.0 in Q1 2019.
• The 5-year median for Non-Current Debt is $27000.0 (2018), against an average of $449750.0.
• Across the five-year window, Non-Current Debt declined 28.89% in 2018 and sank 62.5% in 2019, its largest moves.
• Year by year, Non-Current Debt stood at $14000.0 in 2018, then slipped by 14.29% to $12000.0 in 2019, then jumped by 10816.67% to $1.3 million in 2020, then changed by 0.0% to $1.3 million in 2021, then plunged by 98.85% to $15000.0 in 2022.
• Per Business Quant, the three latest SNOA Non-Current Debt figures stand at $15000.0 (Q4 2022), $15000.0 (Q3 2022), and $15000.0 (Q2 2022).